Anti-inflammatory activity of injectable dexamethasone acetate-loaded nanostructured lipid carriers

Drug Delivery

Volumn 18, Issue 7, 2011, Pages 485-492

  Xu, Xuefan ^a   Zhao, Chunyan ^a   Yang, Hongyun ^a   Jian, Yanlin ^b   Zhang, Zhirong ^a   Huang, Yuan ^a  

^a SICHUAN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

Author keywords

Dexamethasone acetate; inflammations; nanostructured lipid carriers

Indexed keywords

DEXAMETHASONE ACETATE; NANOPARTICLE; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BRAIN; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG LIVER LEVEL; EMULSION; HEART; IN VITRO STUDY; KIDNEY; LIVER; LUNG; NONHUMAN; PARTICLE SIZE; PAW EDEMA; PLEURISY; PRIORITY JOURNAL; RAT; SPLEEN; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; INFLAMMATION; INJECTIONS, INTRAVENOUS; LIPIDS; MALE; MICE; NANOPARTICLES; PARTICLE SIZE; PLEURISY; RATS; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 80052947547     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2011.589087     Document Type: Article

References (40)

1. Azarmi, S., Roa, W,H., Löenberg, R. (2008). Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 60:863-875.
2. Barbro, N.M., Peter, O., Vivian, K.J. (2000). Dexamethasone coupled to albumin is selectively taken up by rat nonparenchymal liver cells and attenuates LPS-induced activation of hepatic cells. J Hepatol. 32:603-611.
3. Cavalli, R., Caputo, O., Gasco, M.R. (2000). Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci. 10:305-309. (Pubitemid 30317466)
4. Carolina, G.G., Nicolas, T., Madeleine, B., Amelie, B., Elias, F. (2007). Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm. 331:153-159.
5. Chin C.T., Chun C.L. (1999). Anti-inflammatory effects of Taiwan folkmedicine Teng-Khia-U on carrageenan-and adjuvantinduced paw edema in rats. J Ethnopharmacol. 64:85-89.
6. China Pharmacopeial Convention. (2005). Chinese Pharmacopoeia. Section 2:184-185.
7. Dik, W.A., McAnulty, R.J., Versnel, M.A., Naber, B.A., Zimmermann, LJ., Laurent, G.J., and Mutsaers, S.E. (2003). Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats. Thorax. 58:765-71. (Pubitemid 37094052)
8. Douglas, T., Young, M.J., Suci, P. (2010). Novel nanoparticles for biofilm targeting. United States Patent USP0021391.
9. Fundaro, A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., and Gasco, M. R., Non-stealth,and stealth solid lipid nanoparticles (SLN). (2000). carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharm Res. 42:337-343.
10. Gert, S., Sheila, 0.B., Toos, D., and Danilo, D.L. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev.17:31-48.
11. Ghamdi MSA., The anti-inflammatory analgesicand antipyretic activityof Nigella Sativa. (2001). J Ethnopharmacol.76:45-48.
12. Grassi, M., Voinovich, D., Franceschinis, E., Perissutti, B., Filipovic-Grcic, J. (2003). Theoretical and experimental study on theophylline release from stearic acid cylindrical delivery systems. J Control Release 92:275-289. (Pubitemid 38366151)
13. Groeneveld, AB. (2002). Vascular pharmacology of acute lung injury and acute respiratory distress syndrome. Vasc. Pharmacol. 39:247-256. (Pubitemid 37490750)
14. Hoogwerf B., Danese R.D. (1999). Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am. 25:489-505. (Pubitemid 29400386)
15. Lange M., Malyusz M. (1994). Improved determination of small amounts of free hydroxyproline in biological fluids. Clin Chem. 409:1735-1738. (Pubitemid 24273097)
16. Lu W., He L.C., Wang C.H., Li Y.H., Zhang S.Q. (2008). The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice. Int J Biol Macromol. 43:320-324.
17. Li, H.P., Li, X., He, G.J., Yi, X.H., Kaplan, A.P. (2004). The influence of dexamethasone on the proliferation and apoptosis of pulmonary inflammatory cells in bleomycininduced pulmonary fibrosis in rats. Respirology. 9:25-32. (Pubitemid 38647766)
18. Löenberg, R., Araujo, L., Von Briesen, H., Rodgers, E., Kreuter, J. (1998). Body distribution of azidothymidine bound to hexylcyanoacrylate nanoparticles after i.v. injection to rats. J Control Release. 50:21-30. (Pubitemid 28044097)
19. Manjunath, K., Venkateswarlu, V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release. 107:215-228. (Pubitemid 41319672)
20. Mehnert, W., Mäder, K. (2001). Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev. 47:165-196. (Pubitemid 32324113)
21. Mei, Z.N., Li, X. K., Wu, Q. R., Hu, S., Yang, X. L. (2005). The research on the anti-inflammatory activity and hepatotoxicity of triptolideloaded solid lipid nanoparticle. Pharmacological Research. 51: 345-351. (Pubitemid 40430808)
22. Moghimi, S.M. (1995). Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block copolymers. Adv Drug Deliv Rev.16:183-193.
23. Müler, R.H., Maaseen, S., Schwarz, C., Mehnert, W. (1997). Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J Control Release. 47:261-269. (Pubitemid 27220209)
24. Müler, R.H., Radtke, M., Wissing, S.A. (2002). Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 242:121-128.
25. Santhi, K., Dhanaraj, S.A., Koshy, M., Ponnusankar, S., Suresh, B. (2000). Study ofbiodistribution of methotrexate-loaded bovine serum albumin nanospheres in mice. Drug Dev Ind Pharm. 26:1293-1296. (Pubitemid 32037426)
26. Scholer, N, Hahn, H, Müler, R.H, Liesenfeld, O. (2002). Effect of lipid matrix and size of solid lipid nanoparticles (SNLC) on the viability and cytokine production of macrophages. Int J Pharm. 231:167-176. (Pubitemid 34033676)
27. Scholer, N, Olbrich, C, Tabatt, K, Müler, R.H, Hahn, H, Liesenfeld O. (2001). Surfactant, but not the size of solid lipid nanoparticles (SNLC) influences viability and cytokine production of macrophages. Int J Pharm. 221:57-67. (Pubitemid 32524035)
28. Souto, E.B., Wissing, S.A., Barbosa, C.M., Müler, R.H. (2004). Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur J. Pharm Biopharm. 58:83-90. (Pubitemid 38781008)
29. Speiser, P. (1990). Lipidnanopellets als Tragersystem fur Arzneimittel zur peroralen Anwendung. European Patent EP0167825.
30. Sun, J.Y., Zhou, Z.F., Liu, F., Chen, G.S. (2007). Pharmacokinetics and tissue distribution of oxymatrine-SLN. Chin Pharm J. 42:1091-1095.
31. Sung, H.K., Dal, W.C., Choon, W.K., Sang, G.K. (2005). Lack of therapeutic improvement of liver fibrosis in rats by dexamethasone in spite of ascites amelioration. Chem Biol Interact. 152:37-47.
32. Vighi, E., Ruozi, B., Montanari, M., Battini, R., Leo, E. (2007). Re-dispersible cationic solid lipid nanoparticles (SLNs) freezedried without cryoprotectors: characterization and ability to bind pEGFP-plasmid. Eur J Pharm Biopharm. 67:320-328. (Pubitemid 47211893)
33. Wang, M.T., Jin, Y., Yang, Y.X., Zhao, C.Y., Yang, H.Y., Xu, X.F., Qin, X., W, Z.D., Zhang, Z.R., Jian, Y.L., Huang. Y. (2010). In vivo biodistribution, anti-inflammatory, and hepatoprotective effects of liver targeting dexamethasone acetate loaded nanostructured lipid carrier system. Int J Nanomedi. 5:487-497.
34. Wang, J.X., Sun, X., Zhang, Z.R. (2002). Enhanced brain targeting by synthesis of 3, 5-dioctanoyl-5-fluoro-2-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm. 54:285-290. (Pubitemid 35341828)
35. Yang, S.C., Lu, L.F., Cai, Y., Zhu, J.B., Liang, B.W., Yang, C.Z. (1999). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release. 59:299-307. (Pubitemid 29238174)
36. Ye, J.S., Wang, Q., Zhou, X.F., Zhang, N. (2008). Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm. 352: 273-279. (Pubitemid 351273921)
37. Yu, B.T., Zhang, Z.R., Zeng, R.J. (2000). Study on the liver targeted 5-fluorouracil solid lipid nanoparticles. Yaoxue Xuebao. 35:704-705.
38. Zara, G.P., Cavalli, R., Fundarò A., Bargoni, A., Caputo, O., Gasco, M.R. (1999). Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res. 40:281-286. (Pubitemid 29435729)
39. Zhang, Z., Dirk, W., Grijpma, J.F. (2006). Poly(trimethylene carbonate) and monomethoxy poly(ethylene glycol)-block-poly(trimethylene carbonate) nanoparticles for the controlled release of dexamethasone. J Control Release. 111:263-270.
40. Zhao, C.Y., Liu, Y., Fan, T.T., Zhou, D., Yang, Y., Jin, Y., Zhang, Z.R., Huang, Y. (2011). A novel strategy for encapsulating poorly soluble drug into nanostructured lipid carriers for intravenous administration. Pharm Dev Technol. 1-14, Early Online.